About Potassium channel subfamily K member 3
Potassium channel subfamily K member 3 (KCNK3) is a protein
from Homo sapiens identified by UniProt accession
O14649, 394 residues long.
MolForge cross-references it against 0 known binders and
268 disease associations.
Target properties
| Protein name | Potassium channel subfamily K member 3 |
| UniProt accession | O14649 |
| Gene | KCNK3 |
| Organism | Homo sapiens |
| Length | 394 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (11)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (268)
Diseases linked to this target (Open Targets).
- pulmonary hypertension, primary, 4 · score 0.73
- delirium · score 0.56
- Agitation · score 0.55
- coronary artery disease · score 0.55
- pain · score 0.54
- ischemia reperfusion injury · score 0.54
- kidney failure · score 0.53
- hypertension · score 0.52
- acute respiratory distress syndrome · score 0.52
- hypotension · score 0.50
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14649-F1 | alphafold | PREDICTED | 74.81 | — |
Amino-acid sequence (394 residues)
MKRQNVRTLA LIVCTFTYLL VGAAVFDALE SEPELIERQR LELRQQELRA RYNLSQGGYE ELERVVLRLK PHKAGVQWRF AGSFYFAITV ITTIGYGHAA PSTDGGKVFC MFYALLGIPL TLVMFQSLGE RINTLVRYLL HRAKKGLGMR RADVSMANMV LIGFFSCIST LCIGAAAFSH YEHWTFFQAY YYCFITLTTI GFGDYVALQK DQALQTQPQY VAFSFVYILT GLTVIGAFLN LVVLRFMTMN AEDEKRDAEH RALLTRNGQA GGGGGGGSAH TTDTASSTAA AGGGGFRNVY AEVLHFQSMC SCLWYKSREK LQYSIPMIIP RDLSTSDTCV EQSHSSPGGG GRYSDTPSRR CLCSGAPRSA ISSVSTGLHS LSTFRGLMKR RSSV
Explore Potassium channel subfamily K member 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets